Lifeboat Foundation

Elon Musk claims OpenAI is using GPT-4 to ‘maximize profits’ instead of ‘for the benefit of humanity.’

The lawsuit claims that the GPT-4 model OpenAI released in March 2023 isn’t just capable of reasoning but is also actually “better at reasoning than average humans,” having scored in the 90th percentile on the Uniform Bar Examination for lawyers. The company is rumored to be developing a more advanced model, known as “Q Star,” that has a stronger claim to being true artificial general intelligence (AGI).

Altman was fired (and subsequently rehired five days later) by OpenAI in 2023 over vague claims that his communication with the board was “hindering its ability to exercise its responsibilities.” The lawsuit filed by Musk alleges that in the days following this event, Altman, Brockman, and Microsoft “exploited Microsoft’s significant leverage over OpenAI” to replace board members with handpicked alternatives that were better approved of by Microsoft.

Continue reading “Elon Musk sues OpenAI for abandoning its mission to benefit humanity” »

A team of Stanford Medicine doctors and biomedical engineers are among the first to integrate a new augmented reality tool into surgical practice. The technology, Apple Vision Pro, is a headset that provides a form of human-computer interaction — it allows its wearer to navigate their surroundings using real-time visual data in combination with virtual elements.

“The novel use of augmented reality in the operating room exemplifies Stanford Medicine’s mission of serving patients in a digitally driven, human-centered care environment,” said Lloyd Minor, dean of the School of Medicine and vice president of medical affairs at Stanford University. “Our health system has long stood at the vanguard for the use of digital technologies in medicine, and I’m proud that through initiatives like RAISE Health, we also define the safe, responsible and equitable use of these innovations.”

Continue reading “Stanford Medicine uses augmented reality for real-time data visualization during surgery” »

Researchers at the National Institutes of Health have identified antibodies targeting a hard-to-spot region of the influenza virus, shedding light on the relatively unexplored “dark side” of the neuraminidase (NA) protein head. The antibodies target a region of the NA protein that is common among many influenza viruses, including H3N2 subtype viruses, and could be a new target for countermeasures. The research, led by scientists at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center, part of NIH, was published today in Immunity.

Influenza, or flu, sickens millions of people across the globe each year and can lead to severe illness and death. While vaccination against influenza reduces the burden of the disease, updated vaccines are needed each season to provide protection against the many strains and subtypes of the rapidly evolving virus. Vaccines that provide protection against a broad range of influenza viruses could prevent outbreaks of new and reemerging flu viruses without the need for yearly vaccine reformulation or vaccinations.

One way to improve influenza vaccines and other countermeasures is to identify new targets on the virus’s surface proteins in “conserved” regions—portions that tend to be relatively unchanged between different strains of the virus. Influenza NA is a surface protein containing a globular head portion and a narrow stalk portion.

Interestingly enough, although Elon Musk’s Neuralink received a great deal of media attention, early in 2023, Synchron published results from its first-in-human study of four patients with severe paralysis who received its first-generation Stentrode neuroprosthesis implant. The implant allowed participants to create digital switches that controlled daily tasks like sending texts and emails, partaking in online banking, and communicating care needs. The study’s findings were published in a paper in JAMA Neurology in January 2023. Then, before September, the first six US patients had the Synchron BCI implanted. The study’s findings are expected by late 2024.

Let’s return to Upgrade. “One part The Six Million Dollar Man, one part Death Wish revenge fantasy” was how critics described the movie. While Death Wish is a 1974 American vigilante action-thriller movie that is partially based on Brian Garfield’s 1972 novel of the same name, the American sci-fi television series The Six Million Dollar Man from the 1970s, based on Martin Caidin’s 1972 novel Cyborg, could be considered a landmark in the context of human-AI symbiosis, although in fantasy’s domain. Oscar Goldman’s opening line in The Six Million Dollar Man was, “Gentlemen, we can rebuild him. We have the technology. We have the capability to make the world’s first bionic man… Better than he was before. Better—stronger—faster.” The term “cyborg” is a portmanteau of the words “cybernetic” and “organism,” which was coined in 1960 by two scientists, Manfred Clynes and Nathan S Kline.

At the moment, “cyborg” doesn’t seem to be a narrative of a distant future, though. Rather, it’s very much a story of today. We are just inches away from becoming cyborgs, perhaps, thanks to the brain chip implants, although Elon Musk perceives that “we are already a cyborg to some degree,” and he may be right. Cyborgs, however, pose a threat, while the dystopian idea of being ruled by Big Brother also haunts. Around the world, chip implants have already sparked heated discussions on a variety of topics, including privacy, the law, technology, medicine, security, politics, and religion. USA Today published a piece headlined “You will get chipped—eventually” as early as August 2017. And an article published in The Atlantic in September 2018 discussed how (not only brain chips but) microchip implants, in general, are evolving from a tech-geek curiosity to a legitimate health utility and that there may not be as many reasons to say “no.” But numerous concerns about privacy and cybersecurity would keep us haunted. It would be extremely difficult for policymakers to formulate laws pertaining to such sensitive yet quickly developing technology.

Professor Nadeem Sarwar is Corporate Vice President, Co-Founder and Head, Transformational Prevention Unit, Novo Nordisk (https://www.novonordisk.com/partnerin…), Co-Chair UK Dementia Mission (a UK Government Ministerial appointment) and Honorary Professor, University of Edinburgh Medical School.

Professor Sarwar joined Novo Nordisk in June 2023 as Corporate Vice President, Co-Founder and Head of Novo Nordisk’s new Transformational Prevention Unit (TPU) whose mission is to increase obesity-free life years, so people live healthier and longer lives. To achieve this, the TPU is establishing an integrated ecosystem that will deliver science-first, empowering, and scalable commercial solutions that predict and pre-empt obesity and its consequences through innovative partnerships, with solutions intending to push the boundaries of what is possible with drugs, genomics, microbiome, digital health, and behavioral science.

Continue reading “Prof Nadeem Sarwar — Corporate VP, Co-Founder & Head, Transformational Prevention Unit, Novo Nordisk” »

New findings reveal that the body undergoes significant, systematic changes across multiple organs during prolonged periods of fasting. The results demonstrate evidence of health benefits beyond weight loss, but also show that any potentially health-altering changes appear to occur only after three days without food.

The study, published in Nature Metabolism, advances our understanding of what’s happening across the body after prolonged periods without food.

By identifying the potential health benefits from fasting and their underlying molecular basis, researchers from Queen Mary University of London’s Precision Healthcare University Research Institute (PHURI) and the Norwegian School of Sports Sciences provide a road map for future research that could lead to therapeutic interventions—including for people that may benefit from fasting but cannot undergo prolonged fasting or fasting-mimicking diets, such as ketogenic diets.

New research from the University of British Columbia reveals a safe path to overcoming food allergies for older children and others who can’t risk consuming allergens orally to build up their resistance.

It’s called sublingual immunotherapy (SLIT), and it involves placing smaller amounts of food allergens under the tongue.

A study conducted by UBC clinical professor and pediatric allergist Dr. Edmond Chan and his team at BC Children’s Hospital Research Institute found SLIT to be as safe and effective for high-risk older children and adolescents as oral immunotherapy is for preschoolers.

Review Article from The New England Journal of Medicine — Wearable Digital Health Technology for Epilepsy.

MIT ’s ultrasound sticker enables continuous monitoring of organ stiffness, revolutionizing the early detection of diseases such as liver and kidney failure.

MIT engineers have developed a small ultrasound sticker that can monitor the stiffness of organs deep inside the body. The sticker, about the size of a postage stamp, can be worn on the skin and is designed to pick up on signs of disease, such as liver and kidney failure and the progression of solid tumors.

In an open-access study published recently in Science Advances, the team reports that the sensor can send sound waves through the skin and into the body, where the waves reflect off internal organs and back out to the sticker. The pattern of the reflected waves can be read as a signature of organ rigidity, which the sticker can measure and track.